Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
Status:
Completed
Trial end date:
2020-09-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to
standard of care is well tolerated and superior to placebo in reducing the risk of
cardiovascular death or heart failure events in adults with chronic heart failure with
reduced ejection fraction (HFrEF).